645P - Capecitabine/cisplatin versus 5-fluorouracil/cisplatin in Chinese patients with advanced and metastatic gastric cancer: Re-analysis of efficacy and...

Date 08 October 2016
Event ESMO 2016 Congress
Session Poster Display
Topics Anticancer Agents
Gastric Cancer
Biological Therapy
Presenter Jia Chen
Citation Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371
Authors J. Chen1, J. Xiong2, J. Wang3, L. Zheng4, Y. Gao5, Z. Guan6
  • 1Department Of Oncology, Jiangsu Cancer Institute and Hospital, 210000 - Nanjing/CN
  • 2Department Of Oncology, 1st Affiliated Hospital of Nanchang Universi, Nanchang/CN
  • 3Department Of Oncology, Shanghai Changzheng Hospital, Shanghai/CN
  • 4Department Of Oncology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai/CN
  • 5Medical Affairs, Shanghai Roche Pharmaceuticals Ltd, Shanghai/CN
  • 6Department Of Oncology, Cancer Centre Sun Yat-Sen University, Guangzhou/CN



This study presents a re-analyses of the efficacy and safety data from the ML17032 trial to confirm the non-inferiority and test the potential superiority of a capecitabine (Xeloda®)/ cisplatin (XP) combination over a 5-fluorouracil (5-FU)/cisplatin (FP) regimen as first-line treatment for advanced gastric cancer (AGC) in Chinese patients.


In this open label phase III trial, patients with advanced gastric cancer (Stage IIIA-IV) with or without metastases were randomized 1:1 to receive Cisplatin (80mg/m2/day IV day 1) with either Capecitabine (1000mg/m2/day PO BID, days1-14) (XP) or 5-FU (800mg/m2/day continuous IV days 1-5) (FP) every 3 weeks. The primary objective was to confirm the non -inferiority of XP over FP for progression free survival (PFS).


A total of 126 Chinese patients (XP-62, FP-64; 75.4% male, median age 55.5 years) were enrolled as the intent to treat population. The per-protocol population consisting of 105 patients (XP-51, FP-54; 64.7% male) served as the primary analysis group for establishing non-inferiority. Median PFS in the XP and FP groups was 7.2 and 4.5 months respectively. The primary efficacy endpoint of PFS was met with an adjusted hazard Ratio (HR) of 0.52 (95% Confidence interval [CI]: [0.32-0.83], p = 0.006). Unadjusted HR for PFS in ITT population was 0.63 (95% CI: [0.42-0.94], p = 0.022). Among secondary efficacy endpoints OS (adjusted HR 0.61 [0.37-1.01], p = 0.053) and TTF (HR 0.54, [0.35, 0.84], p = 0.006) demonstrated a trend towards superiority of XP over FP. Drug exposure was similar among 2 groups in the safety population (XP-58, FP-62, 68.3% male). The most frequent drug related Grade 3/4 AEs were neutropenia (XP-20.7%; FP-17.7%) and gastrointestinal disorders (XP-19.0%; FP-19.4%). The overall incidence of grade 3/4 AEs (XP-43.1%; FP-46.8%), SAEs (XP-1.7%; FP-3.2%), and AEs related to treatment discontinuation (XP-10.3%; FP-16.1%) were comparable among the 2 groups.


XP may demonstrate superiority for PFS and TTF compared to FP in the first-line treatment of Chinese patients with AGC and had a similar safety profile to FP.

Clinical trial identification

ClinicalTrials.gov NCT02563054.

Legal entity responsible for the study



This study was sponsored by Shanghai Roche Pharmaceuticals Ltd, China (ML 17032)


Y. Gao: Employee of Shanghai Roche Pharmaceuticals Ltd. All other authors have declared no conflicts of interest.